论文部分内容阅读
目的回顾性分析多发性骨髓瘤(MM)患者继发第二肿瘤的情况,提高对多发性骨髓瘤继发第二肿瘤的认识。方法回顾性分析2007-2014年医院确诊MM患者94例临床资料,评估所有患者继发第二肿瘤的发生率、第二肿瘤的类型、从治疗至发生第二肿瘤的时间及患者临床表现。结果 91例MM患者治疗过程中继发第二肿瘤4例,发生率4.39%,实体肿瘤及血液肿瘤均有发生。4例患者自诊断MM至第二肿瘤发生平均时间为16月。结论多发性骨髓瘤继发第二肿瘤的发病机制及预后尚不明确,需进一步随访研究,以更好地评估风险与利益,使MM患者获得最佳治疗效果。
Objective To retrospectively analyze the secondary tumor secondary to multiple myeloma (MM) and to improve the understanding of the secondary tumor secondary to multiple myeloma. Methods The clinical data of 94 patients diagnosed with MM from 2007 to 2014 in our hospital were retrospectively analyzed. The incidence of secondary tumor in all patients, the type of secondary tumor, the time from treatment to the occurrence of secondary tumor, and the clinical manifestations of the patients were evaluated. Results 91 patients with MM secondary to the treatment of secondary tumors in 4 cases, the incidence rate of 4.39%, solid tumors and hematological tumors have occurred. Four patients diagnosed MM to the second tumor occurred in an average of 16 months. Conclusion The pathogenesis and prognosis of the second tumor secondary to multiple myeloma are not yet clear. Further follow-up studies are needed to better assess the risks and benefits and to obtain the best therapeutic effect for MM patients.